Vladimir Riabov, Qingyu Xu, Nanni Schmitt, Alexander Streuer, Guo Ge, Lyndsey Bolanos, Mark Wunderlich, Johann-Christoph Jann, Alina Wein, Eva Altrock, Marie Demmerle, Sanjay Mukherjee, Abdullah Mahmood Ali, Felicitas Rapp, Verena Nowak, Nadine Weimer, Julia Obländer, Iris Palme, Melda Göl, Ahmed Jawhar, Ali Darwich, Patrick Wuchter, Christel Weiss, Azra Raza, Jason M Foulks, Daniel T Starczynowski, Feng-Chun Yang, Georgia Metzgeroth, Laurenz Steiner, Mohamad Jawhar, Wolf-Karsten Hofmann, Daniel Nowak
Inhibitors of anti-apoptotic BCL-2 family proteins in combination with chemotherapy and hypomethylating agents (HMAs) are promising therapeutic approaches in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Alvocidib, a cyclin-dependent kinase 9 (CDK9) inhibitor and indirect transcriptional repressor of the anti-apoptotic factor MCL-1, has previously shown clinical activity in AML. Availability of biomarkers for response to the alvocidib + 5- AZA could also extend the rationale of this treatment concept to high-risk MDS...
November 2, 2023: Haematologica